Last reviewed · How we verify
RO4917523
At a glance
| Generic name | RO4917523 |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of RO4917523 in Patients With Treatment Resistant Depression (PHASE2)
- MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy (PHASE2)
- A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers (PHASE1)
- A Study of The Excretion Balance, Pharmacokinetics and Metabolism of A Single Oral Dose of [14C]-Labeled RO4917523 in Healthy Male Volunteers (PHASE1)
- A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers (PHASE1)
- A Pharmacokinetic Study of RO4917523 in Healthy Japanese and Caucasian Subjects (PHASE1)
- A Study With RO4917523 in Patients With Fragile X Syndrome (PHASE2)
- A Human Proof of Concept Study for [11C]-RO5011232 as Radiotracer and Study of the Binding of RO4917523 to Human mGlu5 Brain Receptor at Steady-State in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RO4917523 CI brief — competitive landscape report
- RO4917523 updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI